- $576.41m
- $560.34m
- $414.29m
Accolade Inc reports results for the quarter ended in November - Earnings Summary
Brief: Accolade Q3 Revenue USD 99.4 Million Vs. IBES Estimate USD 96.2 Million
Accolade Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Accolade Announces Repurchase Of $76.5 Million Of 0.50% Convertible Senior Notes Due 2026
U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
U.S. RESEARCH ROUNDUP-Aramark, Mirati Therapeutics, UnitedHealth Group
Brief: Accolade Announces Results For Fiscal Second Quarter 2024
Accolade Inc reports results for the quarter ended in August - Earnings Summary
Brief: Accolade Q2 Revenue USD 96.9 Million Vs. IBES Estimate USD 94.1 Million
Accolade Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-US banks, Circor
U.S. STOCKS ON THE MOVE-Bausch + Lomb, Apple Inc, Madrigal Pharma
U.S. STOCKS ON THE MOVE-Bright Health, Baudax Bio
Accolade rises after forecasting full-year revenue above estimates
U.S. RESEARCH ROUNDUP- Carnival, Nike, Paychex
Brief: Accolade Announces Results For Fiscal First Quarter 2024
Accolade Inc reports results for the quarter ended in May - Earnings Summary
Brief: Accolade Q1 Revenue USD 93.2 Million Vs. Estimate USD 90.3 Million
Accolade Inc expected to post a loss of 62 cents a share - Earnings Preview